Asthma Patents (Class 514/826)
-
Patent number: 5830490Abstract: A method and device for organizing, storing, instructing, and coordinating the combined use of aerosol and oral medications for the treatment of disorders including respiratory tract disorders for the purpose of reducing medication error and increasing therapeutic compliance.Type: GrantFiled: April 4, 1997Date of Patent: November 3, 1998Inventors: Robert E. Weinstein, Alan M. Weinstein
-
Patent number: 5827512Abstract: A method is provided for treating a hypersensitivity disease comprising parenterally administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteracting the effect of at least one cationic toxin released by the eosinophils of said human.Type: GrantFiled: January 28, 1997Date of Patent: October 27, 1998Assignee: Donlar CorporationInventor: Gerald J. Gleich
-
Patent number: 5821260Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: October 13, 1998Assignee: Emory UniversityInventors: Russell M. Medford, Margaret K. Offermann, R. Wayne Alexander, Sampath Parthasarathy
-
Patent number: 5814632Abstract: An immunopotentiating and infection protective agent comprising riboflavin and/or a riboflavin derivative, which is safe for the human, animals or the like, an immunopotentiating and infection protective agent comprising riboflavin and/or a riboflavin derivative and (1) proline and/or glutamine, (2) an antibiotic, or (3) a water-soluble polymer or lecithin, which is safe for the human, animals or the like, and a process for the production thereof.Type: GrantFiled: April 12, 1995Date of Patent: September 29, 1998Assignee: Eisai Co., Ltd.Inventors: Seiichi Araki, Mamoru Suzuki, Masatoshi Fujimoto
-
Patent number: 5798388Abstract: A method for treating the disease state in mammals caused by mammalian cells involved in the inflammatory response is disclosed. Mammalian cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.Type: GrantFiled: September 6, 1996Date of Patent: August 25, 1998Assignee: Cellular Sciences, Inc.Inventor: Stanley E. Katz
-
Patent number: 5792787Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: August 11, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Margaret K. Offermann
-
Patent number: 5786342Abstract: Acemannan has been shown to be effective in treating a number of conditions where the principal mechanism of resolution or cure requires intervention by the patient's immune system. Acemannan has direct stimulatory effects on the immune system. Methods for treating cancer, viral diseases, respiratory and immune regulatory diseases, inflammations, infections and infestations by administering an acetylated mannan derivative, such as acemannan derived from aloe, are described. The method finds use in tissue cultures, animals and plants.Type: GrantFiled: June 5, 1995Date of Patent: July 28, 1998Assignee: Carrington Laboratories, Inc.Inventors: Robert H. Carpenter, Harley R. McDaniel, Bill H. McAnalley
-
Patent number: 5783596Abstract: Dithiocarboxylates, and in particular, dithiocarbamates, block the induced expression of the endothelial cell surface adhesion molecule VCAM-1, and are therefor useful in the treatment of cardiovascular disease, including atherosclerosis, post-angioplasty restenosis, coronary artery diseases, and angina, as well as noncardiovascular inflammatory diseases that are mediated by VCAM-1.Type: GrantFiled: June 7, 1995Date of Patent: July 21, 1998Assignee: Emory UniversityInventors: Russell M. Medford, Margaret K. Offermann, R. Wayne Alexander, Sampath Parthasarathy
-
Patent number: 5780026Abstract: In the present invention, pharmaceutical compositions containing a histamine-added gamma-globulin as an effective component are used as an immunomodulating agent, a suppressive agent for eosinophilia, and as an antiinflammatory agent. The immunomodulating action is unexpectedly different from the action of conventional immunosuppressive agents. Accordingly, the compositions are useful as a pharmaceutical agent for the therapy of diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, etc. and various types of immunodeficiency syndromes. In addition, the pharmaceutical compositions exhibit suppressive action upon hypereosinophilicity. They may be used as a therapeutic agent for infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by malignant tumors. The compositions are excellent antiinflammatory agents.Type: GrantFiled: August 8, 1994Date of Patent: July 14, 1998Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Haruo Yoshii, Yuriko Fukata
-
Patent number: 5773231Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: June 30, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5773209Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: June 30, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5773603Abstract: The present invention relates to adenosinedeaminase inhibitors containing at least one O-alkylated moiety derivative and the pharmaceutically acceptable salts thereof. The pharmaceutical compositions of the present invention include adenosinedeaminase inhibitors containing at least one of the compounds represented by Formula (I): ##STR1## wherein each of R.sub.1, R.sub.2, and R.sub.3 are the same or different and is hydrogen or alkyl;R is hydrogen, alkyl, alkenyl, alkynyl, hydroxyalkynyl, alkoxy, phenyl, hydroxy, amino, alkylamino, phenylamino or halogen;X is hydrogen, alkyl, alkynyl, allyl, methallyl, cycloalkyl, alkyl having one or more hydroxy groups, phenyl, substituted phenyl, alkyl having one or more phenyl groups, alkyl having one or more substituted phenyl groups, bicycloalkyl, naphthylalkyl, acenaphthylenylalkyl or a compound represented by Formula (II) or Formula (III) ##STR2## wherein Z is hydrogen, hydroxy or lower alkoxy;Q is hydrogen or hydroxy;A is --CH.sub.Type: GrantFiled: May 30, 1995Date of Patent: June 30, 1998Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventor: Toshio Yamada
-
Patent number: 5767065Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.Type: GrantFiled: June 6, 1995Date of Patent: June 16, 1998Assignee: Immunex CorporationInventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
-
Patent number: 5766605Abstract: There is disclosed according to the present invention a method for the control of autonomic nerve function in a mammal comprising administering a therapeutically effective amount of botulinum toxin to the mammal. Preferred embodiments include administering the toxin to control the function of an autonomic nerve which contributes to at least one symptom of rhinorrhea, otitis media, excessive salivation, asthma, COPD, excessive stomach acid secretion, spastic colitis or excessive sweating.Type: GrantFiled: April 15, 1994Date of Patent: June 16, 1998Assignee: Mount Sinai School of Medicine of the City University of New YorkInventors: Ira Sanders, Christopher M. Shaari
-
Patent number: 5760090Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.Type: GrantFiled: August 15, 1996Date of Patent: June 2, 1998Assignee: Sepracor, Inc.Inventors: Timothy J. Barberich, James W. Young
-
Patent number: 5750559Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.Type: GrantFiled: August 5, 1994Date of Patent: May 12, 1998Assignee: Sebastiano BiancoInventor: Sebastiano Bianco
-
Patent number: 5750571Abstract: Methods for treating cystic fibrosis are described. The methods involve the administration of a protein enhancing agent, differentiating agent and/or carboxy-compound to a subject afflicted with cystic fibrosis such that mutant cystic fibrosis transmembrane regulator protein present within cystic fibrosis-associated cells becomes functional. Other aspects described include therapeutic compositions and packaged drugs.Type: GrantFiled: December 23, 1996Date of Patent: May 12, 1998Assignee: Genzyme CorporationInventors: Seng Hing Cheng, Shaona Lee Fang, Henry Hoppe, IV, Alan Edward Smith
-
Patent number: 5750351Abstract: A method for the treatment of cardiovascular diseases and noncardiovascular inflammatory diseases that are mediated by VCAM-1 is provided that includes the removal, decrease in the concentration of, or prevention of the formation of oxidized polyunsaturated fatty acids, or interferes with a complex formed between a polyunsaturated fatty acid or an oxidized polyunsaturated fatty acid and a protein or peptide that mediates the expression of VCAM-1. A method is also provided for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through a redox-sensitive pathway, that includes administering an effective amount of a substance that prevents the oxidation of the oxidized signal, and typically, the oxidation of a polyunsaturated fatty acid, or interferes with a complex formed between the oxidized signal and a protein or peptide that mediates the expression of the redox gene.Type: GrantFiled: June 7, 1995Date of Patent: May 12, 1998Assignee: Emory UniversityInventors: Russell M. Medford, R. Wayne Alexander, Sampath Parthasarathy, Bobby V. Khan
-
Patent number: 5744123Abstract: This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate medicament and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant and with the proviso that said medicament is other than salmeterol, salbutamol, fluticasone propionate, beclomethasone dipropionate or a physiologically acceptable salt or solvate thereof. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.Type: GrantFiled: June 5, 1995Date of Patent: April 28, 1998Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5741809Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.Type: GrantFiled: June 6, 1995Date of Patent: April 21, 1998Assignee: Cytomed, Inc.Inventors: Tesfaye Biftu, Xiong Cai, Sajjat Hussoin, Gurmit Grewal, T. Y. Shen
-
Patent number: 5731319Abstract: Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines.Type: GrantFiled: January 13, 1997Date of Patent: March 24, 1998Assignees: Sepracor Inc., University of MassachusettsInventors: A. K. Gunnar Aberg, John R. McCullough, Emil R. Smith
-
Patent number: 5714164Abstract: The invention relates to the use of cucurbitine or extracts of Cucurbitaceae pips for the preparation of a cosmetic or pharmaceutical, in particular dermatological, composition having antiallergic activity, or for the preparation of cosmetic or pharmaceutical compositions having a reduced risk of being allergenic.Type: GrantFiled: June 7, 1995Date of Patent: February 3, 1998Assignee: Parfums Christian DiorInventors: Isabelle Renimel, Patrice Andre
-
Patent number: 5708034Abstract: Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising themSulfonimidamides of the formula I ##STR1## in which at least one of the three substituents R(1), R(2) and R(3) is a benzoylguanidine, and in which the other substituents have the meanings indicated in the claims, are outstandingly suitable as medicaments having action on the cardiovascular system; that is as antiarrhythmic pharmaceuticals having a cardioprotective component as well as for treating ischemically induced damage; also in operative interventions, such as organ transplantation.Type: GrantFiled: October 31, 1996Date of Patent: January 13, 1998Assignee: Hoechst AktiengesellschaftInventors: Heinz-Werner Kleemann, Joachim Brendel, Jan-Robert Schwark, Andreas Weichert, Hans Jochen Lang, Udo Albus, Wolfgang Scholz
-
Patent number: 5698537Abstract: The use of phospholipids of the following formula to reduce the viscosity of mucus in a patient is described: ##STR1## wherein one of X, Y, or Z represent: ##STR2## in which each R represents hydrogen or methyl, and each of the other two of X, Y, or Z represents --CO--R.sup.1 in which R.sup.1 represents linear or branched C.sub.11-21 alkyl or C.sub.11-21 alkenyl, unsubstituted or substituted with one or more substituents selected from the group consisting of halo, C.sub.1-6 linear or branched alkoxy or cyano.Type: GrantFiled: June 18, 1996Date of Patent: December 16, 1997Assignee: Clarion Pharmaceuticals Inc.Inventor: Thaddeus P. Pruss
-
Patent number: 5690910Abstract: A method of treating a patient suffering from antigen-induced asthma who has been challenged with an antigen, or providing chronic treatment to an asthma patient to reduce airway hyperresponsiveness, comprising intrabronchial administration to the patient of a pharmaceutical composition containing in each dose about 0.05 to about 1.0 mg of ultra-low molecular weight heparins (ULMWH), having an average molecular weight of 3,000 daltons or less, per kilogram of patient body weight, Inhalant pharmaceutical compositions for use in the novel treatment method are also provided.Type: GrantFiled: August 18, 1995Date of Patent: November 25, 1997Assignee: Baker Norton Pharmaceuticals, Inc.Inventors: Tahir Ahmed, Samuel Broder, John K. Whisnant
-
Patent number: 5686496Abstract: The new compound of formula ##STR1## may be prepared by conventional methods and used therapeutically as an LTB.sub.4 -receptor antagonist.Type: GrantFiled: March 28, 1997Date of Patent: November 11, 1997Assignee: Boehringer Ingelheim KGInventors: Ralf Anderskewitz, Kurt Schromm, Ernst-Otto Renth, Franz Birke, Armin Fugner, Hubert Heuer, Christopher Meade
-
Patent number: 5681555Abstract: A method is provided for treating a hypersensitivity disease comprising parenterally administering to a human afflicted with such a disease an amount of an anionic polymer effective to counteract the symptoms of a disease selected from the group consisting of bronchial asthma, eosinophil-associated nasal inflammation and vernal conjunctivitis, by counteracting the effect of at least one cationic toxin released by the eosinophils of said human.Type: GrantFiled: September 10, 1993Date of Patent: October 28, 1997Inventor: Gerald J. Gleich
-
Patent number: 5677317Abstract: Compounds of formula I ##STR1## wherein J, B, L, X, m and M have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: April 8, 1996Date of Patent: October 14, 1997Assignee: Zeneca LimitedInventor: Scott Carson Miller
-
Patent number: 5674483Abstract: The present invention relates to a method to protect an animal from a disease involving inflammation by treating that animal with an effective amount of IL-12. The present invention also relates to a method for prescribing treatment for a respiratory disease involving an inflammatory response and a method for monitoring the success of a treatment for a respiratory disease involving an inflammatory response in an animal. Also included in the present invention is a formulation comprising IL-12 and a compound capable of enhancing the effectiveness of the IL-12 at protecting an animal from a disease involving inflammation.Type: GrantFiled: January 31, 1995Date of Patent: October 7, 1997Assignee: National Jewish Medical and Research CenterInventors: Yuan-Po Tu, Charles G. Irvin
-
Patent number: 5674860Abstract: Effective amounts of formoterol and/or a physiologically acceptable salt and/or solvate thereof and budesonide are used in combination for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory respiratory disorder, such as asthma.Type: GrantFiled: October 3, 1994Date of Patent: October 7, 1997Assignee: Astra AktiebolagInventors: Christer Carl Gustav Carling, Jan William Trofast
-
Patent number: 5674898Abstract: Methods and compositions for treating Cystic Fibrosis by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.Type: GrantFiled: June 7, 1993Date of Patent: October 7, 1997Assignee: Genzyme CorporationInventors: Seng Hing Cheng, Shaona Lee Fang, Henry Hoppe, IV, Alan Edward Smith
-
Patent number: 5674471Abstract: The invention relates to a pharmaceutical aerosol formulation consisting essentially of particulate medicament which is salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation contains less than 0.0001% surfactant based upon the weight of medicament, particulate medicament being present in an amount of 0.005% to 5% w/w relative to the total weight of the formulation and having a particle size of less than 100 microns, with the provisos that when said formulation consists of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:18, said salbutamol is present in the form of a physiologically acceptable salt and when said formulation consists of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:7900 or 0.866%.Type: GrantFiled: May 19, 1995Date of Patent: October 7, 1997Assignee: Glaxo Group LimitedInventors: Rachel Ann Akehurst, Anthony James Taylor, David Andrew Wyatt
-
Patent number: 5648373Abstract: Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby.Type: GrantFiled: August 6, 1993Date of Patent: July 15, 1997Assignees: SmithKline Beecham Corporation, The Johns Hopkins UniversityInventors: James David Winkler, Floyd Harold Chilton, III, Deirdre Mary Bernadette Hickey
-
Patent number: 5646156Abstract: The invention concerns the identification on eosinophils of the A3 adenosine receptor subtype and the blockade of said receptor in order to achieve inhibition of eosinophil activation and degranulation.Type: GrantFiled: April 25, 1994Date of Patent: July 8, 1997Assignee: Merck & Co., Inc.Inventors: Marlene A. Jacobson, Robert G. Johnson, Christopher A. Salvatore
-
Patent number: 5631267Abstract: A therapeutic method is provided to treat eosinophil-associated hypersensitivity diseases, such as bronchial asthma, by locally administering to a mammal in need of such treatment, an effective amount of a topical anesthetic, such as lidocaine, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 20, 1996Date of Patent: May 20, 1997Assignee: Mayo Foundation For Medical Education & ResearchInventors: Gerald J. Gleich, Tsukasa Ohnishi, Loren W. Hunt
-
Patent number: 5631245Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Assignee: Biodynamics Pharmaceuticals, Inc.Inventor: Clairmont G. Drube
-
Patent number: 5616556Abstract: Rheumatoid arthritis and osteoarthrosis are treated by administering an effective amount of tetrahydro-WS9326A to a human being or animal suffering from rheumatoid arthritis or osteoarthrosis.Type: GrantFiled: November 18, 1993Date of Patent: April 1, 1997Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Takashi Fujii, Masaaki Tomoi
-
Patent number: 5567590Abstract: Disclosed is a method for diagnosing inflammation in an animal which includes analyzing cells to assess glucocorticoid receptor binding affinity or glucocorticoid receptor number. A low binding affinity and high receptor number are each indicative of inflammation. Also disclosed is a method for treating inflammation in an animal, which inflammation causes glucocorticoid receptor alteration which includes suppressing the activity or expression of cytokines which, in the absence of suppression, alter glucocorticoid receptors. Also disclosed are methods for identifying Type II glucocorticoid receptor binding abnormality and for distinguishing Type I glucocorticoid receptor binding abnormalities from Type II. Further disclosed are treatments for steroid-resistant inflammatory disorders induced by IL-2 and IL-4 which are associated with glucocorticoid receptor binding abnormalities. The treatment includes administering an agent which is an IL-2 suppressor and/or an IL-4 suppressor.Type: GrantFiled: January 6, 1994Date of Patent: October 22, 1996Assignee: National Jewish Center for Immunology and RespiratoryInventors: Donald Y. M. Leung, Stanley J. Szefler, Joseph D. Spahn
-
Patent number: 5565473Abstract: Compounds having the formula I: ##STR1## are leukotriene antagonists and inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.Type: GrantFiled: February 23, 1995Date of Patent: October 15, 1996Assignee: Merck Frosst Canada, Inc.Inventors: Michel L. Belley, Serge Leger, Marc Labelle, Patrick Roy, Yi B. Xiang, Daniel Guay
-
Patent number: 5563156Abstract: This invention relates to novel polyfluorinated alkyl derivatives of certain tripeptides, to the methods for their preparation, the intermediates therefore, to their use in inhibiting thrombin and lung tryptase and in their end-use application as anti-coagulants useful in treating thrombophlebitis and coronary thrombosis and in the treatment of asthma.Type: GrantFiled: May 19, 1995Date of Patent: October 8, 1996Assignee: Merrell Pharmaceuticals Inc.Inventors: Bernhard Neises, Axel Ganzhorn, C eline Tarnus, Robert J. Broersma, Jr.
-
Patent number: 5559109Abstract: A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.Type: GrantFiled: October 7, 1994Date of Patent: September 24, 1996Assignee: Sankko Company, LimitedInventors: Norio Nakamura, Nobuyuki Ohkawa, Takeshi Oshima, Masaaki Miyamoto, Yasuteru Iijima
-
Patent number: 5552437Abstract: Compounds having the Formula I:R.sup.1 R.sup.2 C(OR.sup.3)--Ar.sup.1 --X--Ar.sup.2 --Ar.sup.3Ire inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.Type: GrantFiled: October 27, 1994Date of Patent: September 3, 1996Assignee: Merck Frosst Canada, Inc.Inventors: Daniel Delorme, Daniel Dub e, Yves Ducharme, Erich L. Grimm, Richard Friesen, Carole Lepine
-
Patent number: 5547946Abstract: A method and topical pharmaceutical composition for treating respiratory allergies, allergic rhinitis, allergic conjunctivitis, allergic asthma, and allergy to fur and dust, in which free ion calcium plays a role in a subject. The composition is in the form of oral local and/or nasal liquid solution or suspension for instillation, inhalation or insufflation and includes as active agent, at least one compound selected from the group consisting of: DL-.alpha.-glycerophosphoric acid, glutaric acid and their sodium or potassium salts as the essential active agent. The active agent, when supplied in a sufficient amount, being effective to enable by a reduction in free ion calcium concentration the removal or improvement in symptoms of allergy amenable to said free calcium ion concentration reduction.Type: GrantFiled: November 15, 1993Date of Patent: August 20, 1996Assignee: Farmin S.r.l.Inventor: Giuliano Molinari
-
Patent number: 5547994Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.Type: GrantFiled: November 7, 1994Date of Patent: August 20, 1996Assignee: Sepracor, Inc.Inventors: Timothy J. Barberich, James W. Young
-
Patent number: 5538999Abstract: A compacted body of powdered medicament for use in a device for the administration by inhalation of a medicament in powdered form. The compacted body is made by compressing a loose powder containing the medicament in powdered form under pressure to create sufficient structural integrity in the body to permit metering of several unit doses of the medicament by abrasion of the body in the device.Type: GrantFiled: May 23, 1995Date of Patent: July 23, 1996Assignee: Fisons plcInventors: Andrew R. Clark, John L. Hart
-
Patent number: 5534525Abstract: Compounds of formula I ##STR1## wherein J, B, L, X, m and M have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.Type: GrantFiled: October 31, 1994Date of Patent: July 9, 1996Assignee: Zeneca LimitedInventor: Scott C. Miller
-
Patent number: 5525595Abstract: There are provided novel compounds of the formulae I and II: ##STR1## and their physiologically acceptable salts. The compounds according to the present invention and their physiologically acceptable salts exhibit an antiallergic activity and are useful for treating allergic diseases.Type: GrantFiled: September 26, 1994Date of Patent: June 11, 1996Assignee: Dainippon Ink and Chemicals, Inc.Inventors: Hidetsugu Takagaki, Masayoshi Abe, Yasuo Aoki, Yoshiyuki Sano, Mitsuru Sakai, Nobuyuki Kimura
-
Patent number: 5519049Abstract: Compositions comprising certain macrolides are disclosed which are useful in methods for the treatment of reversible obstructive airway diseases, particularly asthma.Type: GrantFiled: July 16, 1993Date of Patent: May 21, 1996Assignees: Fisons plc, Fujisawa Pharmaceutical Company LimitedInventors: Alan A. Norris, Dale M. Jackson, Sohei Makino, Takeshi Fukuda, Ikuo Akutsu
-
Patent number: 5514652Abstract: The present invention relates to a preparation for the therapy of respiratory tract diseases which contains a basic fibroblast growth factor and/or a homologue thereof as an active ingredient, a preparation for the therapy of respiratory tract diseases which contains a human basic fibroblast growth factor and/or a homologue thereof, produced by microorganisms or cultured cells prepared by genetic recombination, as an active ingredient, and a method for the therapy of respiratory tract diseases by administering any one of these preparations.Type: GrantFiled: October 22, 1993Date of Patent: May 7, 1996Assignee: Kaken Pharmaceutical Co., Ltd.Inventors: Mitsuru Watanuki, Tsutomu Nakamura, Masaru Ogawa
-
Patent number: 5514701Abstract: This invention relates to pyrrolidine derivatives and pharmaceutically acceptable salts, their pharmaceutical compositions, and methods of use as thromboxane A.sub.2 antagonists and/or thromboxane A.sub.2 synthetase inhibitors in the treatment of thrombotic diseases, asthma or nephritis, e.g. of the formula: ##STR1## wherein R.sup.1 is thienyl(lower)alkyl, furyl(lower)alkyl or pyrrolyl(lower)alkyl.Type: GrantFiled: July 23, 1993Date of Patent: May 7, 1996Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Hiroyuki Setoi, Akihiko Sawada, Hirokazu Tanaka, Masashi Hashimoto